Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development
- PMID:9428389
- DOI: 10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co;2-n
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development
Abstract
Background: Bicalutamide (Casodex) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical trials. Clinical trials are currently in progress to further evaluate bicalutamide as monotherapy in patients with advanced stages of disease and as adjuvant or first-line therapy in patients with early-stage disease.
Methods: A review of published trials of bicalutamide focusing on dose-ranging investigations, phase II and phase III monotherapy trials, a phase III trial of combined androgen blockade, and a safety overview.
Results: In dose-ranging trials, bicalutamide doses of 10-200 elicited biochemical, objective, and subjective responses; higher bicalutamide doses (up to 600 mg) have also been evaluated. A 50-mg daily dose of bicalutamide was initially evaluated as monotherapy in phase II and phase III trials; in subsequent trials, a 150-mg daily dose was investigated. A 150-mg daily dose is considered to provide equivalent survival outcome compared with castration in patients with locally advanced prostate cancer, whereas the benefits of a better quality of life and better palliation with the 150-mg daily bicalutamide dose relative to castration in patients with metastatic disease needs to be balanced against the small shortfall (median difference, 42 days) in survival. In combination with a luteinizing hormone-releasing hormone agonist analogue (LHRH-A), a 50-mg daily dose of bicalutamide has equivalent efficacy to a corresponding flutamide (250 mg three times daily) combination regimen. Treatment with the bicalutamide combination regimen resulted in a longer median survival than with the flutamide combination regimen. Bicalutamide is well tolerated when used as monotherapy or in combination with a LHRH-A. The benefits of bicalutamide as monotherapy include retention of libido and sexual potency and as combination therapy a lower incidence of diarrhea relative to flutamide.
Conclusions: A 50-mg daily dose of bicalutamide is sufficient when given in combination with an agent, such as a LHRH-A, that lowers serum testosterone, but higher doses of bicalutamide may be needed when the drug is given as monotherapy. Bicalutamide, 50-mg daily, is a logical first choice for antiandrogen therapy when used in combination with an LHRH-A for the treatment of patients with advanced prostate cancer. Bicalutamide 150-mg daily is considered an effective monotherapy for use in patients with locally advanced disease. Additional clinical trials are currently in progress to further evaluate bicalutamide as a monotherapy for advanced prostate cancer and to assess its value as adjuvant or first-line therapy for early-stage prostate cancer.
Similar articles
- Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.Schellhammer P, et al.Urology. 1996 Jan;47(1A Suppl):54-60; discussion 80-4. doi: 10.1016/s0090-4295(96)80010-0.Urology. 1996.PMID:8560679Clinical Trial.
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.Schellhammer P, et al.Urology. 1995 May;45(5):745-52. doi: 10.1016/s0090-4295(99)80077-6.Urology. 1995.PMID:7538237Clinical Trial.
- A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.Soloway MS, et al.Eur Urol. 1996;29 Suppl 2:105-9. doi: 10.1159/000473848.Eur Urol. 1996.PMID:8717471Clinical Trial.
- Bicalutamide dosages used in the treatment of prostate cancer.Kolvenbag GJ, Nash A.Kolvenbag GJ, et al.Prostate. 1999 Apr 1;39(1):47-53. doi: 10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co;2-x.Prostate. 1999.PMID:10221266Review.
- Clinical progress with a new antiandrogen, Casodex (bicalutamide).Blackledge GR.Blackledge GR.Eur Urol. 1996;29 Suppl 2:96-104. doi: 10.1159/000473847.Eur Urol. 1996.PMID:8717470Review.
Cited by
- Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT.Gao W, et al.Endocrinology. 2004 Dec;145(12):5420-8. doi: 10.1210/en.2004-0627. Epub 2004 Aug 12.Endocrinology. 2004.PMID:15308613Free PMC article.
- Spongian diterpenoids inhibit androgen receptor activity.Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD.Yang YC, et al.Mol Cancer Ther. 2013 May;12(5):621-31. doi: 10.1158/1535-7163.MCT-12-0978. Epub 2013 Feb 26.Mol Cancer Ther. 2013.PMID:23443807Free PMC article.
- Chemical modulation of transcription factors.Wiedemann B, Weisner J, Rauh D.Wiedemann B, et al.Medchemcomm. 2018 Jul 11;9(8):1249-1272. doi: 10.1039/c8md00273h. eCollection 2018 Aug 1.Medchemcomm. 2018.PMID:30151079Free PMC article.Review.
- Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.Pepe A, Pamment M, Kim YS, Lee S, Lee MJ, Beebe K, Filikov A, Neckers L, Trepel JB, Malhotra SV.Pepe A, et al.J Med Chem. 2013 Nov 14;56(21):8280-97. doi: 10.1021/jm301714s. Epub 2013 Oct 30.J Med Chem. 2013.PMID:24044500Free PMC article.
- 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G.Ferroni C, et al.J Med Chem. 2017 Apr 13;60(7):3082-3093. doi: 10.1021/acs.jmedchem.7b00105. Epub 2017 Mar 20.J Med Chem. 2017.PMID:28272894Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical